- Previous Close
0.0701 - Open
0.0691 - Bid --
- Ask 0.0940 x 100
- Day's Range
0.0700 - 0.0700 - 52 Week Range
0.0700 - 0.0700 - Volume
8,327 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.11
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
silexion.comRecent News: SLXNW
View MoreCompare To: SLXNW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLXNW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.13%
Return on Equity (ttm)
-116.66%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.35M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-305.62k